Determining the Actual Prevalence of Hepatitis B in Khyber Pakhtunkhwa-Pakistan: A Meta-Analysis

Najeeb Ullah Khan1,*, Ali Zalan1, Arnolfo Petruzziello3, Iftikhar ud din2, Fazle Haq2 and Yousaf Hayat2

1Institute of Biotechnology and Genetic Engineering (Health Division), The University of Agriculture Peshawar, Peshawar, Pakistan
2Department of Mathematics, Stats & Computer Science, The University of Agriculture Peshawar, Peshawar, Pakistan
3Virology and Molecular Biology Unit “V. Tridente”, Istituto Nazionale Tumori - Fondazione “G. Pascale”, IRCCS Italia, Naples, Italy

Received: August 28, 2017 Revised: September 26, 2017 Accepted: December 28, 2017

Abstract:

Background:
Hepatitis B is considered the most dangerous among the five types of Hepatitis, as it is clinically asymptomatic. It can silently damage the liver over many years without being diagnosed. Hepatitis B is one of the top risks of liver complications in Khyber Pakhtunkhwa (KP), a province of Pakistan, with an average prevalence rate of 2.70%.

Aims:
We aimed to carefully review the previously published data on prevalence of Hepatitis B Virus (HBV) in KP-Pakistan and use the statistical approach to obtain more precise estimate of the prevalence of HBV in KP-Pakistan. This study on one hand will provide a more reliable and consolidated estimate (pooled estimate) of HBV in the stated region, on the other hand, it enabled us to judge the heterogeneity among the estimates found from these studies. The study is intended to provide more authentic prevalence record and help government/ non-government organizations and health professionals, which plan to initiate HBV prevention programs in KP-Pakistan.

Methods:
A meta-analysis was performed based on studies found in literature search from electronic databases and bibliography on the prevalence of HBV in KP-Pakistan from 2007 to 2017. Abstracts and results of twenty papers were thoroughly studied and the data were extracted. The findings from these studies were distributed in two groups (general and population at high risk) constituting 15 and 5 studies respectively.

Results:
The combined prevalence by considering random model for the general population of KP-Pakistan was observed to be 2.71%, while population at high risk was reasonably high i.e. 5.64%. By comparing this prevalence rate to the highest global prevalence of HBV in the adult population of Western Pacific Region (6.2%), significant (p-value= 0.000) heterogeneity was observed among the estimates in each group. However, the funnel plot provides a symmetric look, eliminating the effect of publication bias. We can say that HBV has an alarming prevalence rate in KP-Pakistan. However, HBV is thrice more prevalent in male population of KP-Pakistan than the female population.

* Address correspondence to this author at the Institute of Biotechnology and Genetic Engineering (Health Division), The University of Agriculture Peshawar, Peshawar, Pakistan; Tel: +92-3339732955; E-mails: najeebkhan@aup.edu.pk, naji_banni@yahoo.com
The above results lead that HBV infection has reached an alarming state in KP-Pakistan, though projects like Prime Minister’s Program for Prevention & Control of Hepatitis which are contributing in improving the health of the people of KP by trying to prevent and control the incidence of HBV. More massive vaccination and awareness programs should be initiated to prevent the spread of HBV on urgent basis. Provision of diagnostics and treatment facilities against HBV in healthcare units of KP-Pakistan should be assured.

Keywords: Hepatitis B, Liver, Prevalence, Meta analyze, Infection, Healthcare.

1. INTRODUCTION

Hepatitis B is a deadly liver infection, which is caused by the Hepatitis B Virus (HBV). Approximately, 257 million people are living with HBV infection that resulted in 887,000 deaths in 2015 [1]. The highest prevalence of HBV was reported in the adult population of Western Pacific Region (6.2%) and African Region (6.1%) [2, 3]. HBV infection can result in many liver complications including chronic hepatitis, cirrhosis, and hepatocellular carcinoma [4]. The major risk factors for HBV are the unhygienic and substandard methods of surgeries, use of unsterilized instruments, tattooing, piercing, blood transfusion and the drugs abuse. The risk factors for developing HBV infection also include working in a healthcare setting, dialysis, acupuncture, tattooing, sharing razors or toothbrushes with an infected person, travelling in countries where HBV is endemic, and residence in an institution [5].

HBV is endemic in Pakistan with prevalence rate as high as 3% [6]. High prevalence of HBV in Pakistan is observed in people who have a low economic status. It is vital to control HBV in Pakistan because 67.5% of the population belongs to rural areas of low economic status [7]. Effective treatments, mass immunization programs, and safe injection techniques are important for eliminating HBV infection. Effective vaccines against HBV are available since 1982 [8]. Adefovir is an effective prescription medicine used to treat infections with HBV [9]. Entecavir, sold under the brand name Baraclude, is an antiviral medication used in the treatment of HBV infection. It proves to be an emerging effective drug against the HBV [10].

The prevalence of HBV in Pakistan has been quoted about 3–5% in general population and about 10–20% in population at high risk [6]. Actual determination of HBV infection in Pakistan is difficult because of poor management and record keeping. With the aim to investigate the actual prevalence of HBV in KP-Pakistan, meta-analysis of published data from KP-Pakistan was performed. A total of twenty papers from 2007–2017 were selected dividing in two groups (general and population at high risk). The extracted data was statistically analyzed and compared with the world’s highest prevalence rate, indicating that the prevalence of HBV in KP-Pakistan is an alarming situation.

2. MATERIALS AND METHODS

2.1. Literature Searching Strategy

Studies of interest from 2007–2017 (up to 14th July, 2017) were selected using search engine of the PubMed Database, Google scholar and the relevant search strategies (prevalence of HBV in KPK, prevalence of HBV in N.W.F.P, prevalence of HBV in Khyber Pakhtunkhwa). We have also searched the database of NCBI and Researchgate.net, by using the keywords [HBV in Khyber Pakhtunkhwa]. A total of 20 studies (abstracts and results) were thoroughly studied and selected for the analysis. The data (Table 1) regarding, region, study population (general or high-risk), lab techniques used for markers detection, total sample size, percentages and numbers of HBV was identified and subjected for statistical analysis.

Table 1. Characteristics summary of the included studies.
Determining the Actual Prevalence of Hepatitis B

The advent of latest and sophisticated statistical tools enabled us to reanalyze the secondary type of data. Furthermore, different studies on the same topic may confusingly differ in their findings. One discipline, which considerably improves secondary analysis, is termed as meta-analysis. It is a known fact that the research activities are rapidly growing; there is an urgent need to integrate all the studies on the same topic. Meta-analysis refers to the statistical analysis of results obtained from individual studies, in order to come up with a combine and comprehensive result.

The collected studies were distributed into two groups, first group consist of 15 studies and were considered as representative of the general population, while the second group consists of 5 studies that represent the population at high risk. The meta-analysis tools of pooling the estimates, forest plot, heterogeneity testing and assessing publication bias were used. Further, 95% confidence intervals (CIs) and Z and P value of the respective event rates were obtained. The corresponding forest plot provided a better picture of event rates (prevalence when multiplied by 100) along with 95% CIs.

Next the combined estimate of these studies was found by considering both fixed and random effect model; in order to judge how much these studies are in accordance with each other, we used the heterogeneity test (I-square). To assess the biasness, symmetry and divergence of the results from respective studies, a funnel plot was used.

3. RESULTS

3.1. Statistical Analysis

A total of 20 articles were identified through searching records and included in the study after screening the titles and abstracts. The characteristics of the studies are summarized (Table 1). The HBV prevalence rate in the studies, which represents the general population varies from 1.10% of blood donors to 21.1% of the internally displaced population (IDPs). The combined estimate of the general population based on 15 studies was 2.8% (CI 2.7% to 2.9%), which dropped to 2.3% when a study (IDPs) was excluded and consequently the prevalence in the risk group (based on 6 studies) rose to 6.1%. All the assessments included in the study showed significance prevalece rate of HBV in the respective population. The forest plot (Table 2) gives a better view of the estimates along with their CIs. It is evident that apart from two studies i.e. one of IDPs and the drug addicts, where the prevalence was unusually high (21.1% and 22.4% respectively), the corresponding CIs was large too, the rest of the studies showed more conformity and precision of estimates.

In the computation of general population estimate, the study of blood donor C constituted 32042 individuals and consequently attained maximum weight (34.11%). It was followed by the study based on HBV in students and employees, which obtained 12.98% weightage. In the high risk category, the prevalence of the hospital patients reported extra ordinary high weightage of 88.84% while the remaining 11.16% was distributed among the remaining 4 studies.
3.2. Pooled Estimates for Fixed and Random Model

The combined prevalence of the fixed effect for the general population of KP was 2.80%. This estimate is highly significant (p-value = 0.00) and carries huge precision as indicated by the width of 95% CIs (2.68 to 2.93). Further, the result of the Q test indicates that the population of 15 studies was shown to possess highly significant heterogeneity (p-value = 0.00). The high \( I^2 \) values (exceeding 75%) showed that most of the variability across studies is due to heterogeneity rather than chance, reflecting the inconsistency between the studies. Hence it will be appropriate to consider mixed or random effect model instead of fixed effect model.

The combined mixed effect estimate of group 2 populations was reasonably high as 5.25%, having greater width of 95% CIs, ranging from 4.29 to 10.35% than the fixed effect estimate. The prevalence rate was again significantly (p-value= 0.00) greater than the hypothesized value of zero. The population at higher risk now has a greater prevalence rate (5.64%) than before, with much wider CIs (2.99 to 10.35%) than the fixed effect estimate. The overall mixed effect estimate was calculated to be 3.44% but with least precision as the corresponding 95% CIs (2.39 to 4.91) was much wider than that found before. All these mixed effect estimates are statistically highly significant (Table 3).

### Table 2. Overall statistics of the included studies.

| Study                  | Events | Total | Proportion | 95%−CI     | Weight (fixed) | Weight (random) |
|------------------------|--------|-------|------------|------------|----------------|-----------------|
| **Group = General**    |        |       |            |            |                |                 |
| Health Care Workers    | 3      | 125   | 0.02       | [0.00; 0.07]| 0.1%           | 3.5%            |
| Random                 | 5      | 180   | 0.03       | [0.01; 0.06]| 0.1%           | 4.0%            |
| Students & Employees   | 6      | 200   | 0.03       | [0.01; 0.06]| 0.2%           | 4.2%            |
| Health Care Workers    | 18     | 824   | 0.02       | [0.01; 0.03]| 0.5%           | 4.9%            |
| Elective Eye Surgery   | 26     | 1416  | 0.02       | [0.01; 0.03]| 0.8%           | 5.0%            |
| Healthy Blood Donors   | 66     | 1300  | 0.05       | [0.04; 0.06]| 1.9%           | 5.2%            |
| Pregnant women         | 77     | 5607  | 0.01       | [0.01; 0.02]| 2.3%           | 5.2%            |
| Blood Donors           | 81     | 3915  | 0.02       | [0.02; 0.03]| 2.4%           | 5.3%            |
| Blood Donors           | 93     | 8439  | 0.01       | [0.01; 0.01]| 2.8%           | 5.3%            |
| Pregnant women         | 119    | 10288 | 0.01       | [0.01; 0.01]| 3.6%           | 5.3%            |
| IDPs                   | 200    | 950   | 0.21       | [0.19; 0.24]| 4.9%           | 5.3%            |
| Random                 | 164    | 4680  | 0.04       | [0.03; 0.04]| 4.9%           | 5.3%            |
| Civil Servants         | 167    | 4639  | 0.04       | [0.03; 0.04]| 4.9%           | 5.3%            |
| Blood Donors           | 244    | 7148  | 0.03       | [0.03; 0.04]| 7.2%           | 5.3%            |
| Blood Donors           | 631    | 32042 | 0.02       | [0.02; 0.02]| 19.0%          | 5.3%            |
| **Fixed effect model** | 81755  |       | 0.03       | [0.03; 0.03]| 55.8%          | --              |
| **Random effects model** | 81755  |       | 0.03       | [0.02; 0.04]| 74.5%          | --              |
| **Group = High Risk**  |        |       |            |            |                |                 |
| Thalassaemia Patients  | 10     | 170   | 0.06       | [0.03; 0.11]| 0.3%           | 4.6%            |
| Orthopaedics Patients  | 33     | 1630  | 0.02       | [0.01; 0.03]| 1.0%           | 5.1%            |
| Drug Abusers           | 56     | 252   | 0.22       | [0.17; 0.28]| 1.3%           | 5.2%            |
| Afghan Patients        | 78     | 2166  | 0.04       | [0.03; 0.04]| 2.3%           | 5.2%            |
| Patients of a hospital | 1349   | 25944 | 0.05       | [0.05; 0.05]| 39.3%          | 5.4%            |
| **Fixed effect model** | 30162  |       | 0.05       | [0.05; 0.06]| 44.2%          | --              |
| **Random effects model** | 30162  |       | 0.06       | [0.03; 0.10]| 25.5%          | --              |
| **Fixed effect model** | 111917 |       | 0.04       | [0.04; 0.04]| 100.0%         | --              |
| **Random effects model** | 111917 |       | 0.03       | [0.02; 0.05]| 100.0%         | --              |
Table 3. Fixed effect analysis of overall, general and high risk groups.

| Group | No. of Studies | Point Estimate | Lower Limit | Upper Limit | Z-value | P-value | Q-value | df (Q) | P-value | I-Squared |
|-------|----------------|----------------|-------------|-------------|---------|---------|---------|--------|---------|-----------|
| Fixed Effect Analysis | 1 | 15 | 2.80 | 2.68 | 2.93 | -151.01 | 0.00 | 1147.11 | 14 | 0.00 | 98.78 |
| | 2 | 5 | 5.25 | 4.99 | 5.51 | -109.79 | 0.00 | 162.83 | 4 | 0.00 | 97.54 |
| | Overall | 20 | 3.71 | 3.59 | 3.83 | -185.79 | 0.00 | 1650.65 | 19 | 0.00 | 98.85 |
| Mixed effects analysis of general, high-risk and overall populations | 1 | 15 | 2.71 | 1.74 | 4.21 | -15.48 | 0.00 | – | – | – |
| | 2 | 5 | 5.64 | 2.99 | 10.35 | -8.37 | 0.00 | – | – | – |
| | Overall | 20 | 3.44 | 2.39 | 4.91 | -17.50 | 0.00 | – | – | – |

3.3. Assessment of Publication Bias

Although the event rates (prevalence) greatly vary, so does their standard error. Mostly (in 16 studies), the standard error is lower than 0.3. The funnel plot (Fig. 1) of all the 20 studies shows that circles are scattered on both sides of the funnel but still, they were fairly symmetrical, a symptom that refers to no specification bias in the Meta-analysis we carried out. The line in the middle indicates the overall estimate obtained from the meta-analysis, which is the weighted mean of the studies included in the analysis.

![Funnel Plot of Standard Error by Logit event rate](image)

**Fig. (1).** Funerl plot of overall 20 studies.

3.4. Funnel Plot of the General and High-Risk Populations

Funnel plot of the general population (Fig. 2) based on 15 studies depicts the same picture as stated above for all the 20 studies. Variations among the plotted dots were high but still the funnel depicted symmetrical shape referring to no publication bias. For the high-risk population (Fig. 3), the dotted points are widely scattered, reflecting the difference in standard error of these studies but still evenly distributed around the central line, giving symmetrical shape to the funnel plot thus no publication bias.

![Funnel Plot of Standard Error by Logit event rate](image)
4. DISCUSSION

HBV is one of the major public health problems worldwide especially in developing countries including Pakistan [30]. HBV is clinically asymptomatic over many years after infection that can silently damage the liver, which leads to HCC [31]. Pakistan has a huge burden of HBV infection over many years with an average prevalence rate of 3-5% in general population and 10-20% in population with high risk [6]. Our objective was to document the actual prevalence of HBV in KP-Pakistan by reviewing the recent prevalence studies (2007 to 2017). The best way to analyze our data was to Meta analyze them so that we could come up with a more comprehensive result. The selected data were divided into two groups; a general and a high-risk group. The combined prevalence of the fixed effect for the general population of KP was 2.80%, which doesn’t seem much high but the combined fixed effect estimate of the population at risk was reasonably high i.e. 5.25%. The high-risk group had drug abusers and other types of patients in it. The prevalence in drug abusers was found to be as high as 22.40% [27], which is quite alarming. Drug abuse places people at specific hazard for contracting viral hepatitis. Taking part in hazardous sexual conduct and drug abuse places, people get in danger of contracting HBV. They are at high hazard for contracting HBV from shared needles. On account of the addiction, drug abusers over and again take part in these dangerous practices, which can make them “super carriers” of the infection. In the group of general population, the IDPs had a prevalence rate as high as 21.05% [7]. Pakistan has been antagonistically influenced by the war on terror. It has caused calamity on an unfathomable scale. Pakistan, being the forefront state, has directed a number of operations against activists in the KP region. In the result of the military
operation named Zarb-e-Azb, a great many individuals fled from their homes and incidentally relocated to safe territories to look for shelter [32]. The issues, which IDPs confront, are quick alleviation, protection, sustenance, medicine, clean drinking water, sanitation and so forth. These factors have led to the spread of lethal diseases like HBV. The government of KP must map IDPs in order to stop the spread of deadly diseases including HBV and the record proves that on their return, they would face and generate lots of health challenges.

In pregnant women, the percentage of prevalence (as recorded by two publications) was found to be 1.16% [12] and 1.37% [23]. The lowest prevalence 1.10% was found in the blood donors [11] but it will need further confirmation with huge numbers of subjects. KP has approximately high prevalence rate of 3.0% with a population of more than 30.52 million; KP has more than 10 million HBV carriers and contributes a large proportion to the worldwide pool of HBV carriers. It is vital to complete more examinations to better describe the disease transmission of HBV, for distinguishing high prevalence regions, and all the while to concentrate on enhancing general wellbeing measures to combat HBV and lessen its weight.

CONCLUSION

Taking everything into account, there is a high weight of perpetual HBV virus among the residents of KP. HBV is a preventable disease and to be sure one that can be treated by immunization or vaccination. Tending to the difficulties of HBV in KP-Pakistan will require multi-level methodologies that incorporate populace wide instructive mediations and a fortifying of the Pakhtunkhwa’s wellbeing framework. There is pressing requirement for the legislature of KP and its universal accomplices to reorganize HBV control.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

HUMAN AND ANIMAL RIGHTS

No Animals/Humans were used for studies that are base of this research.

CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

NUK designed the study and wrote the manuscript. AZ collected the data and helped in the writing of the manuscript. IUD, FH and YH statically analyzed the data, and AP reviewed the manuscript.

REFERENCES

[1] WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection Guidel Prev care Treat Pers with chronic Hepat b Infect. 2015.
[2] Hennessey K, Mendoza-Aldana J, Bayutas B, Lorenzo-Mariano KM, Diorditsa S. Hepatitis B control in the World Health Organization’s Western Pacific Region: targets, strategies, status. Vaccine 2013; 31(Suppl. 9): 385-92. [http://dx.doi.org/10.1016/j.vaccine.2012.10.082] [PMID: 24331026]
[3] Schweitzer A, Horn J, Nikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 2015; 386(10003): 1546-55. [http://dx.doi.org/10.1016/S0140-6736(15)61412-X] [PMID: 26231459]
[4] Liang TJ, Hepatitis B. Hepatitis B: The virus and disease. Hepatology 2009; 49(5)(Suppl.): S13-21. [http://dx.doi.org/10.1002/hep.22881] [PMID: 19399811]
[5] Liaw Y-F, Chu C-M. Hepatitis B virus infection. Lancet 2009; 373(9663): 582-92. [http://dx.doi.org/10.1016/S0140-6736(09)60207-5] [PMID: 19217993]
[6] Ali M, Idrees M, Ali L, Hussain A, Ur Rehman I, Saleem S, et al. Hepatitis B virus in Pakistan: A systematic review of prevalence, risk factors, awareness status and genotypes. Virol J [Internet] BioMed Central Ltd 2011. Available from: http://virologyj.biomedcentral.com/articles/10.1186/1743-422X-8-102
The prevalence of HBV infection in the cohort of IDPs of war against terrorism in Malakand Division of Northern Pakistan. BMC Infect Dis 2011; 11: 176. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3141412&tool=pmcentrez&rendertype=abstract

Cassidy A, Mossman S, Olivieri A, De Ridder M, Leroux-Roels G. Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity. Expert Rev Vaccines 2011; 10(12): 1709-15. http://dx.doi.org/10.1586/erv.11.151 [PMID: 22085174]

van Bömmel F, Wünsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40(6): 1421-5. [PMID: 15565615]

Cassidy A, Mossman S, Olivieri A, De Ridder M, Leroux-Roels G. Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity. Expert Rev Vaccines 2011; 10(12): 1709-15. http://dx.doi.org/10.1586/erv.11.151 [PMID: 22085174]

Sciences E. Prevalence of Hepatitis B virus, Hepatitis C virus and HIV in blood donors of different areas of Khyber Pakhtoonkhwa, Pakistan. Prevalence of Hepatitis B virus, Hepatitis C virus and HIV in blood donors of different areas of Khyber Pakhtoonkhwa. 2016; 9: pp. 304-9.

Ahmad I. Prevalence of Hepatitis B and C Viral Infection Among Pregnant Women in Peshawar. Pakistan: Hepat Mon 2016.

Khan ZA, Shafiq M, Shahab F. Frequency and risk factors of hepatitis B and C in Afghan patients presenting to tertiary care hospital in Peshawar. 2015; 65: pp. 5-8.

Naoman M, Hussain MM, Ali G, Ishaq MS, Khan M. Frequency and Risk Factors of Hepatitis B and Hepatitis C in Peshawar Khyber Pakhtunkhwa. 2013.

Munir M, Shams S, Lodhi MA, Parveen Z. Prevalence of Hepatitis B virus in the Students, and Employees of Abdul Wali Khan University Mardan Shankar Campus. 2013.

Article O, Ud I, Khattak DIN, Shah M, Ahmed I, Rehman A, et al. Frequency of hepatitis B and hepatitis C in multitransfused beta thalassaemia major patients in district swat. 2013.

Mehr MT, Khan H, Nisa QU, Imran NU. Frequency of hepatitis B and C infection in newly recruited civil servants in Khyber Pakhtunkhwa Khyber Medical University Journal. 2013; 26: 5(2).

Attaullah S, Khan S. Prevalence of HBV and HBV vaccination coverage in health care workers of tertiary hospitals of Peshawar, Pakistan. Virol J [Internet] BioMed Central Ltd 2011. Available from: http://www.virologyj.com/content/8/1/275

Khattak MF, Salamat N, Bhatti FA, Qureshi TZ. Seroprevalence of hepatitis B, C and HIV in blood donors in northern Pakistan. J Pak Med Assoc 2002; 52(9): 398-402. [PMID: 12532573]

Shah SM, Khattak IU, Ali A, Tariq M. Seropositivity for hepatitis B and C in voluntary blood donors. J Ayub Med Coll Abbottabad 2010; 22(3): 149-51. [PMID: 22338442]

Khan NU, Siddique L, Ali I, Iqbal A, Munir I, Rashid F, et al. Prevalence of hepatitis B in the blood donors of N W.F.P and FATA regions and the current scenario of HBV infection in Pakistan. Afr J Biotechnol 2010; 9: 6162-6. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed9&AN=2010576396

Majid A, Khan MS, Ullah S. Rising prevalence of Hepatitis B and C and risk factors at District Headquarter Teaching Hospital Bannu, Khyber-Pakhtunkhwa. J Coll Physicians Surg Pak 2010; 20(7): 492-3. [PMID: 20642957]

Khattak ST, Ali Marwat M, Khattak Ju, Khan TM, Naheed T. Comparison of frequency of hepatitis B and hepatitis C in pregnant women in urban and rural area of district Swat. J Ayub Med Coll Abbottabad 2009; 21(2): 12-5. [PMID: 20524459]

Bangash MH, Bangash TH, Alam S. Prevalence of Hepatitis B and Hepatitis C among healthy blood donors at kurram Agency. J Postgrad Med Inst 2009; 23: 140-5.

Ahmad A, Ahmad B, Ali A, Ahmad Y. Seroprevalence of HBsAg and anti-HCV in general healthy population of Swat district with frequency of different HCV genotypes. Pak J Med Sci 2009; 25: 744-8.

Sarwar J, Gul N, Idris M, Anis-ur-Rehman, Farid J, Adeel MY. Seroprevalence of hepatitis B and hepatitis C in health care workers in Abbottabad. J Ayub Med Coll Abbottabad 2008; 20(3): 27-9. [PMID: 19610509]

Ahmad A, Ahmad B, Ali A, Ahmad Y. Seroprevalence of HBsAg and anti-HCV in general healthy population of Swat district with frequency of different HCV genotypes. Pak J Med Sci 2009; 25: 744-8.

Article O, Khan AJ, Siddiqui TR, America N. Prevalence and importance of hepatitis B & C screening in cases undergoing elective eye surgery. Pak J ophthalmol 2007; 23(1): 39-44.
[29] Khan MS, Janil M, Jan S, Zardad S, Sultan S, Sahibzada AS. Prevalence of hepatitis ‘B’ and ‘C’ in orthopaedics patients at Ayub Teaching Hospital Abbottabad. J Ayub Med Coll Abbottabad 2007; 19(4): 82-4. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed8&AN=18693606 [PMID: 18693606]

[30] Franco E, Bagnato B, Marino MG, et al. Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol 2012; 4(3): 74-80. [http://dx.doi.org/10.4254/wjh.v4.i3.74] [PMID: 22489259]

[31] Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 2012; 25(1): 142-63. [http://dx.doi.org/10.1128/CMR.00018-11] [PMID: 22232374]

[32] Javaid U. Zarb-e-Azb and the State of Security in Pakistan. JRSP 2016; 53: 159-70.

© 2018 Khan et al.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.